Assignee
ALLGENESIS BIOTHERAPEUTICS INC
TW·9 granted patents·6 pending applications·20 citations·filing 2016–2025
Top patents by PatentIndex Score
15 records- 0194US11723955B1VEGFR fusion protein pharmaceutical compositionALLGENESIS BIOTHERAPEUTICS INC·Filed 2022·Granted Aug 15, 2023·4 cites·7 claims
- 0287US10154994B2Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereofALLGENESIS BIOTHERAPEUTICS INC·Filed 2017·Granted Dec 18, 2018·9 cites·24 claims
- 0384US11192927B2Fusion proteins for inhibiting angiogenesisALLGENESIS BIOTHERAPEUTICS INC·Filed 2019·Granted Dec 7, 2021·3 cites·18 claims
- 0479US11369600B2Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereofALLGENESIS BIOTHERAPEUTICS INC·Filed 2018·Granted Jun 28, 2022·1 cites·15 claims
- 0579US11299531B2Fusion protein comprising a ligand binding domain of VEGF and PDGFALLGENESIS BIOTHERAPEUTICS INC·Filed 2016·Granted Apr 12, 2022·2 cites·18 claims
- 0679US2024408083A1Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereofALLGENESIS BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0778US12318428B2VEGFR fusion protein pharmaceutical compositionALLGENESIS BIOTHERAPEUTICS INC·Filed 2023·Granted Jun 3, 2025·0 cites·20 claims
- 0878US2025051404A1Fusion proteins for inhibiting angiogenesisALLGENESIS BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0973US2025319157A1Vegfr fusion protein pharmaceutical compositionALLGENESIS BIOTHERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1071US2022280506A1Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereofALLGENESIS BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1166US2024374753A1Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseasesALLGENESIS BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1262US12152057B2Fusion proteins for inhibiting angiogenesisALLGENESIS BIOTHERAPEUTICS INC·Filed 2020·Granted Nov 26, 2024·0 cites·7 claims
- 1362US10870635B2Compounds and their use as BACE1 inhibitorsALLGENESIS BIOTHERAPEUTICS INC·Filed 2016·Granted Dec 22, 2020·1 cites·12 claims
- 1457US10961203B2Crystalline forms of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-phenylamino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinoneALLGENESIS BIOTHERAPEUTICS INC·Filed 2019·Granted Mar 30, 2021·0 cites·20 claims
- 1554US2018170979A1Fusion proteins for inhibiting angiogenesisALLGENESIS BIOTHERAPEUTICS INC·Filed 2016·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →